Skip to content

Observational vs. Ablative Treatment for Low-grade Squamous Intraepithelial Lesions.

Observational vs. Ablative Treatment for Low-grade Squamous Intraepithelial Lesions. Retrospective Paired Cohort Study.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02331550
Enrollment
250
Registered
2015-01-06
Start date
2014-01-31
Completion date
2014-12-31
Last updated
2016-09-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

LSIL, Low-Grade Squamous Intraepithelial Lesions

Keywords

Low-Grade Squamous Intraepithelial Lesions

Brief summary

To evaluate the rate of regression and progression of low-grade squamous intraepithelial lesion comparing expectant vs. ablative treatment.

Interventions

Use of an ablative treatment (cryotherapy) for the management of Low-Grade Squamous Intraepithelial Lesions of the cervix.

Patients diagnosed with Low-Grade Squamous Intraepithelial Lesions were managed with observation and evaluation at 6 and 12 months after diagnosis.

Sponsors

Saint Thomas Hospital, Panama
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Healthy volunteers
No

Inclusion criteria

* Diagnosis of Low-Grade Squamous Intraepithelial Lesion by cervical cytology. * Positive Biopsy for Low-Grade Squamous Intraepithelial Lesion after colposcopy.

Exclusion criteria

* Serological detection of human immunodeficiency virus (HIV).

Design outcomes

Primary

MeasureTime frame
Number of patients diagnosed with Low-Grade Squamous Intraepithelial Lesions that progressed to a higher level lesion (High Grade or cervical cancer) when evaluated at 6 and 12 months after diagnosis.12 months

Secondary

MeasureTime frame
Number of patients diagnosed with Low-Grade Squamous Intraepithelial Lesions that regressed to a higher level lesion (High Grade or cervical cancer) when evaluated at 6 and 12 months after diagnosis.12 months

Countries

Panama

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026